# EDGAR Filing Document

**Accession Number:** 0001346830
**File Stem:** 0001104659-26-038128
**Filing Date:** 2026-4
**Character Count:** 8113
**Document Hash:** 7bad5611668c690deccb03a7ca2401a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-038128.hdr.sgml**: 20260401

**ACCESSION NUMBER**: 0001104659-26-038128

**CONFORMED SUBMISSION TYPE**: POS EX

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260401

**DATE AS OF CHANGE**: 20260401

**EFFECTIVENESS DATE**: 20260401

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tvardi Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001346830
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** POS EX
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-287675
- **FILM NUMBER:** 26824542

**BUSINESS ADDRESS:**
- **STREET 1:** 3 SUGAR CREEK CTR. BLVD.
- **STREET 2:** STE 525
- **CITY:** SUGAR LAND
- **STATE:** TX
- **ZIP:** 77478
- **BUSINESS PHONE:** (713) 489-8654

**MAIL ADDRESS:**
- **STREET 1:** 3 SUGAR CREEK CTR. BLVD.
- **STREET 2:** STE 525
- **CITY:** SUGAR LAND
- **STATE:** TX
- **ZIP:** 77478

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cara Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20100721

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cara Therapeutics Inc
- **DATE OF NAME CHANGE:** 20051213

**As filed with the Securities and Exchange Commission on April 1, 2026**

**Registration No. 333-287675** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Post-Effective Amendment No. 1**

**TO**

**FORM S-1**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**TVARDI THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **2834** | **75-3175693** |
| **(State or other jurisdiction of incorporation or<br> organization)** | **(Primary Standard Industrial Classification<br> Code Number)** | **(I.R.S. Employer Identification No.)** |

---

**3 Sugar Creek Ctr. Blvd.**

**Suite 525**

**Sugar Land, TX 77478**

**(713) 489-8654**

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive office)**

**Imran Alibhai**

**Chief Executive Officer**

**3 Sugar Creek Ctr. Blvd.**

**Suite 525**

**Sugar Land, TX 77478**

**(713) 489-8654**

**(Name, address, including zip code, and telephone number, including area code, of agent for service)**

***Copies to:***

**Divakar Gupta**

**Madison A. Jones**

**Cooley LLP**

**55 Hudson Yards**

**New York, NY 10001**

**(212) 479-6000**

**Approximate date of commencement of proposed sale to the public**: From time to time after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box: ⌧

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ◻

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ⌧ (333-287675)

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | x | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**This Post-Effective Amendment No. 1 shall become effective upon filing with the Securities and Exchange Commission in accordance with Rule 462(d) under the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE**

This Post-Effective Amendment No. 1 (this "Amendment") to the Registration Statement on Form S-1 of Tvardi Therapeutics, Inc., as amended (File No. 333-287675), initially filed on May 30, 2025 and declared effective by the Securities and Exchange Commission on November 8, 2025 (the "Registration Statement"), is being filed as an exhibit-only filing solely to file the consent of Deloitte & Touche LLP with respect to its report dated March 31, 2026 relating to the financial statements of Tvardi Therapeutics, Inc. contained in its Annual Report on Form 10-K for the year ended December 31, 2025 and included in the Prospectus Supplement No. 1 dated April 1, 2026 filed pursuant to Rule 424(b)(3), filed herewith as Exhibit 23.1 (the "Consent"). Accordingly, this Amendment consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement and the Consent. The prospectus and the balance of Part II of the Registration Statement are unchanged hereby and have been omitted.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 16. Exhibits and Financial Statement Schedules.**

**(a) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| [23.1\*](tm2610047d2_ex23-1.htm) | [Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.](tm2610047d2_ex23-1.htm) |

---

\* Filed herewith

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Houston, State of Texas, on April 1, 2026.

---

| | |
|:---|:---|
| **TVARDI THERAPEUTICS, INC.** | **TVARDI THERAPEUTICS, INC.** |
| By: | /s/ Imran Alibhai |
| Name: | Imran Alibhai |
| Title: | Chief Executive Officer |

---

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Imran Alibhai | Chief Executive Officer and Director | April 1, 2026 |
| Imran Alibhai | (*Principal Executive Officer)* |  |
| /s/ Dan Conn | Chief Financial Officer | April 1, 2026 |
| Dan Conn | *(Principal Financial Officer)* |  |
| /s/ Stephen O'Brien | Vice President, Finance and Corporate Controller | April 1, 2026 |
| Stephen O'Brien | *(Principal Accounting Officer)* |  |
| \* | Chairman of the Board of Directors | April 1, 2026 |
| Sujal Shah |  |  |
| \* | Director | April 1, 2026 |
| Wallace Hall |  |  |
| \* | Director | April 1, 2026 |
| Michael S. Wyzga |  |  |
| \* | Director | April 1, 2026 |
| Cynthia Smith |  |  |
| \* | Director | April 1, 2026 |
| Susan Shiff |  |  |

---

---

| | |
|:---|:---|
| By: | /s/ Imran Alibhai |
| Name: | Imran Alibhai |
| Title: | Attorney-in-fact |

---

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the use in Registration Statement No. 333-287675 on Form S-1 of our report dated March 31, 2026 relating to the financial statements of Tvardi Therapeutics, Inc., appearing in the Prospectus Supplement, which is part of this Registration Statement.

/s/ Deloitte & Touche LLP

Houston, Texas

April 1, 2026